Behavioral and neurotransmitter abnormalities in mice deficient for Parkin, DJ-1 and superoxide dismutase

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Hennis, Meghan R ^a   Seamans, Katherine W ^a   Marvin, Marian A ^a   Casey, Bradford H ^a   Goldberg, Matthew S ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; DJ-1 PROTEIN, MOUSE; DOPAMINE; MANGANESE SUPEROXIDE DISMUTASE; ONCOPROTEIN; PARKIN; SUPEROXIDE DISMUTASE; UBIQUITIN PROTEIN LIGASE;

ANIMAL; ANIMAL BEHAVIOR; CORPUS STRIATUM; CROSS BREEDING; DEFICIENCY; DOPAMINERGIC NERVE CELL; GENETICS; KNOCKOUT MOUSE; METABOLISM; MOUSE; OXIDATIVE STRESS; PATHOLOGY; SUBSTANTIA NIGRA;

ANIMALS; BEHAVIOR, ANIMAL; CORPUS STRIATUM; CROSSES, GENETIC; DOPAMINE; DOPAMINERGIC NEURONS; MICE; MICE, KNOCKOUT; ONCOGENE PROTEINS; OXIDATIVE STRESS; SUBSTANTIA NIGRA; SUPEROXIDE DISMUTASE; UBIQUITIN-PROTEIN LIGASES;

EID: 84893547450     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0084894     Document Type: Article

References (99)

1. Corti O, Lesage S, Brice A (2011) What genetics tells us about the causes and mechanisms of Parkinson's disease. Physiol Rev 91: 1161-1218. doi:10.1152/physrev.00022.2010. PubMed: 22013209.
2. Dawson TM, Ko HS, Dawson VL (2010) Genetic animal models of Parkinson's disease. Neuron 66: 646-661. doi:10.1016/j.neuron.2010.04.034. PubMed: 20547124.
3. Hattori N (2012) Autosomal dominant parkinsonism: its etiologies and differential diagnoses. Parkinsonism Relat Disord 18 Suppl 1: S1-S3. doi:10.1016/j.parkreldis.2011.06.011. PubMed: 22166400.
4. Horowitz MP, Greenamyre JT (2010) Gene-environment interactions in Parkinson's disease: the importance of animal modeling. Clin Pharmacol Ther 88: 467-474. doi:10.1038/clpt.2010.138. PubMed: 20811350.
5. Lopez G, Sidransky E (2010) Autosomal recessive mutations in the development of Parkinson's disease. Biomark Med 4: 713-721. doi:10.2217/bmm.10. 96. PubMed: 20945983.
6. Varcin M, Bentea E, Michotte Y, Sarre S (2012) Oxidative stress in genetic mouse models of Parkinson's disease. Oxid Med Cell Longev 2012: 624925.
7. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y et al. (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392: 605-608. doi:10.1038/33416. PubMed: 9560156.
8. Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ et al. (2003) Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299: 256-259. doi:10.1126/science.1077209. PubMed: 12446870.
9. Kuhn K, Zhu XR, Lubbert H, Stichel CC (2004) Parkin expression in the developing mouse. Brain Res. Dev Brain Res 149: 131-142. doi:10.1016/j. devbrainres.2004.02.001.
10. Shimura H, Hattori N, Kubo S, Yoshikawa M, Kitada T et al. (1999) Immunohistochemical and subcellular localization of Parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients. Ann Neurol 45: 668-672. doi:10.1002/1531-8249(199905)45:5. PubMed: 10319893.
11. Shang H, Lang D, Jean-Marc B, Kaelin-Lang A (2004) Localization of DJ-1 mRNA in the mouse brain. Neurosci Lett 367: 273-277. doi:10.1016/j.neulet.2004. 06.002. PubMed: 15337248.
12. Stichel CC, Augustin M, Kühn K, Zhu XR, Engels P et al. (2000) Parkin expression in the adult mouse brain. Eur J Neurosci 12: 4181-4194. doi:10.1111/j.1460-9568.2000.01314.x. PubMed: 11122330.
13. Xie Z, Zhuang X, Chen L (2009) DJ-1 mRNA anatomical localization and cell type identification in the mouse brain. Neurosci Lett 465: 214-219. doi:10.1016/j.neulet.2009.09.024. PubMed: 19766170.
14. Andres-Mateos E, Perier C, Zhang L, Blanchard-Fillion B, Greco TM et al. (2007) DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. Proc Natl Acad Sci U S A 104: 14807-14812. doi:10.1073/pnas. 0703219104. PubMed: 17766438.
15. Chandran JS, Lin X, Zapata A, Höke A, Shimoji M et al. (2008) Progressive behavioral deficits in DJ-1-deficient mice are associated with normal nigrostriatal function. Neurobiol Dis 29: 505-514. doi:10.1016/j.nbd. 2007.11.011. PubMed: 18187333.
16. Fleming SM, Chesselet MF (2006) Behavioral phenotypes and pharmacology in genetic mouse models of Parkinsonism. Behav Pharmacol 17: 383-391. doi:10.1097/00008877-200609000-00004. PubMed: 16940759.
17. Fleming SM, Fernagut PO, Chesselet MF (2005) Genetic mouse models of parkinsonism: strengths and limitations. NeuroRx 2: 495-503. doi:10.1602/neurorx.2.3.495. PubMed: 16389313.
18. Frank-Cannon TC, Tran T, Ruhn KA, Martinez TN, Hong J et al. (2008) Parkin deficiency increases vulnerability to inflammation-related nigral degeneration. J Neurosci 28: 10825-10834. doi:10.1523/JNEUROSCI.3001-08.2008. PubMed: 18945890.
19. Goldberg MS, Fleming SM, Palacino JJ, Cepeda C, Lam HA et al. (2003) Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem 278: 43628-43635. doi:10.1074/jbc.M308947200. PubMed: 12930822.
20. Goldberg MS, Pisani A, Haburcak M, Vortherms TA, Kitada T et al. (2005) Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron 45: 489-496. doi:10.1016/j.neuron.2005.01.041. PubMed: 15721235.
21. Itier JM, Ibanez P, Mena MA, Abbas N, Cohen-Salmon C et al. (2003) Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum Mol Genet 12: 2277-2291. doi:10.1093/hmg/ddg239. PubMed: 12915482.
22. Kim RH, Smith PD, Aleyasin H, Hayley S, Mount MP et al. (2005) Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6- tetrahydropyrindine (MPTP) and oxidative stress. Proc Natl Acad Sci U S A 102: 5215-5220. doi:10.1073/pnas.0501282102. PubMed: 15784737.
23. Kitada T, Tong Y, Gautier CA, Shen J (2009) Absence of nigral degeneration in aged parkin/DJ-1/PINK1 triple knockout mice. J Neurochem 111: 696-702. doi:10.1111/j.1471-4159.2009.06350.x. PubMed: 19694908.
24. Manning-Boǧ AB, Caudle WM, Perez XA, Reaney SH, Paletzki R et al. (2007) Increased vulnerability of nigrostriatal terminals in DJ-1-deficient mice is mediated by the dopamine transporter. Neurobiol Dis 27: 141-150. doi:10.1016/j.nbd.2007.03.014. PubMed: 17560790.
25. Palacino JJ, Sagi D, Goldberg MS, Krauss S, Motz C et al. (2004) Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem 279: 18614-18622. doi:10.1074/jbc.M401135200. PubMed: 14985362.
26. Perez FA, Curtis WR, Palmiter RD (2005) Parkin-deficient mice are not more sensitive to 6-hydroxydopamine or methamphetamine neurotoxicity. BMC Neurosci 6: 71. doi:10.1186/1471-2202-6-71. PubMed: 16375772.
27. Perez FA, Palmiter RD (2005) Parkin-deficient mice are not a robust model of parkinsonism. Proc Natl Acad Sci U S A 102: 2174-2179. doi:10.1073/pnas. 0409598102. PubMed: 15684050.
28. Pham TT, Giesert F, Röthig A, Floss T, Kallnik M et al. (2010) DJ-1-deficient mice show less TH-positive neurons in the ventral tegmental area and exhibit non-motoric behavioural impairments. Genes Brain Behav 9: 305-317. doi:10.1111/j.1601-183X.2009.00559.x. PubMed: 20039949.
29. Rousseaux MW, Marcogliese PC, Qu D, Hewitt SJ, Seang S et al. (2012) Progressive dopaminergic cell loss with unilateral-to-bilateral progression in a genetic model of Parkinson disease. Proc Natl Acad Sci U S A 109: 15918-15923. doi:10.1073/pnas.1205102109. PubMed: 23019375.
30. Sato S, Chiba T, Nishiyama S, Kakiuchi T, Tsukada H et al. (2006) Decline of striatal dopamine release in parkin-deficient mice shown by ex vivo autoradiography. J Neurosci Res 84: 1350-1357. doi:10.1002/jnr.21032. PubMed: 16941649.
31. Von Coelln R, Thomas B, Savitt JM, Lim KL, Sasaki M et al. (2004) Loss of locus coeruleus neurons and reduced startle in parkin null mice. Proc Natl Acad Sci U S A 101: 10744-10749. doi:10.1073/pnas.0401297101. PubMed: 15249681.
32. Yang W, Chen L, Ding Y, Zhuang X, Kang UJ (2007) Paraquat induces dopaminergic dysfunction and proteasome impairment in DJ-1-deficient mice. Hum Mol Genet 16: 2900-2910. doi:10.1093/hmg/ddm249. PubMed: 17823202.
33. Zhu XR, Maskri L, Herold C, Bader V, Stichel CC et al. (2007) Nonmotor behavioural impairments in parkin-deficient mice. Eur J Neurosci 26: 1902-1911. doi:10.1111/j.1460-9568.2007.05812.x. PubMed: 17883413.
34. Paterna JC, Leng A, Weber E, Feldon J, Büeler H (2007) DJ-1 and Parkin modulate dopamine-dependent behavior and inhibit MPTPinduced nigral dopamine neuron loss in mice. Mol Ther 15: 698-704. PubMed: 17299411.
35. Bian M, Liu J, Hong X, Yu M, Huang Y et al. (2012) Overexpression of parkin ameliorates dopaminergic neurodegeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. PLOS ONE 7: e39953. doi:10.1371/journal.pone.0039953. PubMed: 22792139.
36. Hayashi T, Ishimori C, Takahashi-Niki K, Taira T, Kim YC et al. (2009) DJ-1 binds to mitochondrial complex I and maintains its activity. Biochem Biophys Res Commun 390: 667-672. doi:10.1016/j.bbrc.2009.10.025. PubMed: 19822128.
37. Junn E, Jang WH, Zhao X, Jeong BS, Mouradian MM (2009) Mitochondrial localization of DJ-1 leads to enhanced neuroprotection. J Neurosci Res 87: 123-129. doi:10.1002/jnr.21831. PubMed: 18711745.
38. Lo Bianco C, Schneider BL, Bauer M, Sajadi A, Brice A et al. (2004) Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease. Proc Natl Acad Sci U S A 101: 17510-17515. doi:10.1073/pnas.0405313101. PubMed: 15576511.
39. Vercammen L, Van der Perren A, Vaudano E, Gijsbers R, Debyser Z et al. (2006) Parkin protects against neurotoxicity in the 6-hydroxydopamine rat model for Parkinson's disease. Mol Ther 14: 716-723. doi:10.1016/j.ymthe.2006.06.009. PubMed: 16914382.
40. Zhou W, Freed CR (2005) DJ-1 up-regulates glutathione synthesis during oxidative stress and inhibits A53T alpha-synuclein toxicity. J Biol Chem 280: 43150-43158. doi:10.1074/jbc.M507124200. PubMed: 16227205.
41. Shimura H, Hattori N, Kubo Si, Mizuno Y, Asakawa S et al. (2000) Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 25: 302-305. doi:10.1038/77060. PubMed: 10888878.
42. Narendra D, Tanaka A, Suen DF, Youle RJ (2008) Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol 183: 795-803. doi:10.1083/jcb.200809125. PubMed: 19029340.
43. Hauser DN, Hastings TG (2013) Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism. Neurobiol Dis 51: 35-42. doi:10.1016/j.nbd.2012.10.011. PubMed: 23064436.
44. Müftüoglu M, Elibol B, Dalmizrak O, Ercan A, Kulaksiz G et al. (2004) Mitochondrial complex I and IV activities in leukocytes from patients with parkin mutations. Mov Disord 19: 544-548. doi:10.1002/mds.10695. PubMed: 15133818.
45. Rodríguez-Navarro JA, Casarejos MJ, Menéndez J, Solano RM, Rodal I et al. (2007) Mortality, oxidative stress and tau accumulation during ageing in parkin null mice. J Neurochem 103: 98-114. PubMed: 17623040.
46. Vincent A, Briggs L, Chatwin GF, Emery E, Tomlins R et al. (2012) parkin-induced defects in neurophysiology and locomotion are generated by metabolic dysfunction and not oxidative stress. Hum Mol Genet 21: 1760-1769. doi:10.1093/hmg/ddr609. PubMed: 22215442.
47. Vincow ES, Merrihew G, Thomas RE, Shulman NJ, Beyer RP et al. (2013) The PINK1-Parkin pathway promotes both mitophagy and selective respiratory chain turnover in vivo. Proc Natl Acad Sci U S A 110: 6400-6405. doi:10.1073/pnas. 1221132110. PubMed: 23509287.
48. Vinish M, Anand A, Prabhakar S (2011) Altered oxidative stress levels in Indian Parkinson's disease patients with PARK2 mutations. Acta Biochim Pol 58: 165-169. PubMed: 21584286.
49. Choi J, Sullards MC, Olzmann JA, Rees HD, Weintraub ST et al. (2006) Oxidative Damage of DJ-1 Is Linked to Sporadic Parkinson and Alzheimer Diseases. J Biol Chem 281: 10816-10824. doi:10.1074/jbc.M509079200. PubMed: 16517609.
50. Blackinton J, Lakshminarasimhan M, Thomas KJ, Ahmad R, Greggio E et al. (2009) Formation of a stabilized cysteine sulfinic acid is critical for the mitochondrial function of the parkinsonism protein DJ-1. J Biol Chem 284: 6476-6485. PubMed: 19124468.
51. Canet-Avilés RM, Wilson MA, Miller DW, Ahmad R, McLendon C et al. (2004) The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc Natl Acad Sci U S A 101: 9103-9108. doi:10.1073/pnas.0402959101. PubMed: 15181200.
52. Lev N, Ickowicz D, Melamed E, Offen D (2008) Oxidative insults induce DJ-1 upregulation and redistribution: implications for neuroprotection. Neurotoxicology 29: 397-405. doi:10.1016/j.neuro.2008.01.007. PubMed: 18377993.
53. Mullett SJ, Hinkle DA (2011) DJ-1 deficiency in astrocytes selectively enhances mitochondrial Complex I inhibitor-induced neurotoxicity. J Neurochem 117: 375-387. doi:10.1111/j.1471-4159.2011.07175.x. PubMed: 21219333.
54. Alam ZI, Jenner A, Daniel SE, Lees AJ, Cairns N et al. (1997) Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem 69: 1196-1203. PubMed: 9282943.
55. Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y et al. (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 52: 381-389. doi:10.1111/j.1471-4159.1989.tb09133.x. PubMed: 2911023.
56. Zhang J, Perry G, Smith MA, Robertson D, Olson SJ et al. (1999) Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am J Pathol 154: 1423-1429. doi:10.1016/S0002-9440(10)65396-5. PubMed: 10329595.
57. Floor E, Wetzel MG (1998) Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J Neurochem 70: 268-275. PubMed: 9422371.
58. Liddell JR, Robinson SR, Dringen R, Bishop GM (2010) Astrocytes retain their antioxidant capacity into advanced old age. Glia 58: 1500-1509. PubMed: 20648641.
59. Belluzzi E, Bisaglia M, Lazzarini E, Tabares LC, Beltramini M et al. (2012) Human SOD2 modification by dopamine quinones affects enzymatic activity by promoting its aggregation: possible implications for Parkinson's disease. PLOS ONE 7: e38026. doi:10.1371/journal.pone.0038026. PubMed: 22723845.
60. Sun SY, An CN, Pu XP (2012) DJ-1 protein protects dopaminergic neurons against 6-OHDA/MG-132-induced neurotoxicity in rats. Brain. Res Bull 88: 609-616. doi:10.1016/j.brainresbull.2012.05.013.
61. Wang Z, Liu J, Chen S, Wang Y, Cao L et al. (2011) DJ-1 modulates the expression of Cu/Zn-superoxide dismutase-1 through the Erk1/2-Elk1 pathway in neuroprotection. Ann Neurol 70: 591-599. doi:10.1002/ana.22514. PubMed: 21796667.
62. Wang D, Qian L, Xiong H, Liu J, Neckameyer WS et al. (2006) Antioxidants protect PINK1-dependent dopaminergic neurons in Drosophila. Proc Natl Acad Sci U S A 103: 13520-13525. doi:10.1073/pnas.0604661103. PubMed: 16938835.
63. Andreassen OA, Ferrante RJ, Dedeoglu A, Albers DW, Klivenyi P et al. (2001) Mice with a partial deficiency of manganese superoxide dismutase show increased vulnerability to the mitochondrial toxins malonate, 3-nitropropionic acid, and MPTP. Exp Neurol 167: 189-195. doi:10.1006/exnr.2000.7525. PubMed: 11161607.
64. Callio J, Oury TD, Chu CT (2005) Manganese superoxide dismutase protects against 6-hydroxydopamine injury in mouse brains. J Biol Chem 280: 18536-18542. PubMed: 15755737.
65. Boll MC, Alcaraz-Zubeldia M, Montes S, Rios C (2008) Free copper, ferroxidase and SOD1 activities, lipid peroxidation and NO(x) content in the CSF. A different marker profile in four neurodegenerative diseases. Neurochem Res 33: 1717-1723. doi:10.1007/s11064-008-9610-3. PubMed: 18307039.
66. Kunikowska G, Jenner P (2003) Alterations in m-RNA expression for Cu,Zn-superoxide dismutase and glutathione peroxidase in the basal ganglia of MPTP-treated marmosets and patients with Parkinson's disease. Brain Res 968: 206-218. doi:10.1016/S0006-8993(03)02240-6. PubMed: 12663090.
67. Ihara Y, Chuda M, Kuroda S, Hayabara T (1999) Hydroxyl radical and superoxide dismutase in blood of patients with Parkinson's disease: relationship to clinical data. J Neurol Sci 170: 90-95. doi:10.1016/S0022-510X(99)00192-6. PubMed: 10561523.
68. Andrews AM, Ladenheim B, Epstein CJ, Cadet JL, Murphy DL (1996) Transgenic mice with high levels of superoxide dismutase activity are protected from the neurotoxic effects of 2′-NH2-MPTP on serotonergic and noradrenergic nerve terminals. Mol Pharmacol 50: 1511-1519. PubMed: 8967972.
69. Asanuma M, Hirata H, Cadet JL (1998) Attenuation of 6-hydroxydopamine- induced dopaminergic nigrostriatal lesions in superoxide dismutase transgenic mice. Neuroscience 85: 907-917. doi:10.1016/S0306-4522(97)00665-9. PubMed: 9639283.
70. Hirata H, Asanuma M, Cadet JL (1998) Superoxide radicals are mediators of the effects of methamphetamine on Zif268 (Egr-1, NGFIA) in the brain: evidence from using CuZn superoxide dismutase transgenic mice. Brain. Resour - Mol Brain Res 58: 209-216. doi:10.1016/S0169-328X(98)00055-2.
71. Barkats M, Horellou P, Colin P, Millecamps S, Faucon-Biguet N et al. (2006) 1-methyl-4-phenylpyridinium neurotoxicity is attenuated by adenoviral gene transfer of human Cu/Zn superoxide dismutase. J Neurosci Res 83: 233-242. doi:10.1002/jnr.20696. PubMed: 16353238.
72. Tripanichkul W, Sripanichkulchai K, Duce JA, Finkelstein DI (2007) 17beta-estradiol reduces nitrotyrosine immunoreactivity and increases SOD1 and SOD2 immunoreactivity in nigral neurons in male mice following MPTP insult. Brain Res 1164: 24-31. doi:10.1016/j.brainres.2007.05.076. PubMed: 17640623.
73. Li Y, Huang TT, Carlson EJ, Melov S, Ursell PC et al. (1995) Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase. Nat Genet 11: 376-381. doi:10.1038/ng1295-376. PubMed: 7493016.
74. Van Remmen H, Salvador C, Yang H, Huang TT, Epstein CJ et al. (1999) Characterization of the antioxidant status of the heterozygous manganese superoxide dismutase knockout mouse. Arch Biochem Biophys 363: 91-97. doi:10.1006/abbi.1998.1060. PubMed: 10049502.
75. Williams MD, Van Remmen H, Conrad CC, Huang TT, Epstein CJ et al. (1998) Increased oxidative damage is correlated to altered mitochondrial function in heterozygous manganese superoxide dismutase knockout mice. J Biol Chem 273: 28510-28515. doi:10.1074/jbc.273.43.28510. PubMed: 9774481.
76. Hennis MR, Marvin MA, Taylor CM 2nd, Goldberg MS (2013) Surprising behavioral and neurochemical enhancements in mice with combined mutations linked to Parkinson's disease. Neurobiol Dis 62C: 113-123. PubMed: 24075852.
77. Kondo T, Reaume AG, Huang TT, Carlson E, Murakami K et al. (1997) Reduction of CuZn-superoxide dismutase activity exacerbates neuronal cell injury and edema formation after transient focal cerebral ischemia. J Neurosci 17: 4180-4189. PubMed: 9151735.
78. Nguyen TA, Frank-Cannon T, Martinez TN, Ruhn KA, Marvin M et al. (2013) Analysis of inflammation-related nigral degeneration and locomotor function in DJ-1(-/-) mice. J Neuroinflammation 10: 50. doi:10.1186/1742-2094-10-50. PubMed: 23622116.
79. Ramaswamy S, McBride JL, Han I, Berry-Kravis EM, Zhou L et al. (2009) Intrastriatal CERE-120 (AAV-Neurturin) protects striatal and cortical neurons and delays motor deficits in a transgenic mouse model of Huntington's disease. Neurobiol Dis 34: 40-50. doi:10.1016/j.nbd.2008.12.005. PubMed: 19150499.
80. Chen L, Cagniard B, Mathews T, Jones S, Koh HC et al. (2005) Agedependent motor deficits and dopaminergic dysfunction in DJ-1 null mice. J Biol Chem 280: 21418-21426. doi:10.1074/jbc.M413955200. PubMed: 15799973.
81. Perucho J, Casarejos MJ, Rubio I, Rodriguez-Navarro JA, Gómez A et al. (2010) The effects of parkin suppression on the behaviour, amyloid processing, and cell survival in APP mutant transgenic mice. Exp Neurol 221: 54-67. doi:10.1016/j.expneurol.2009.09.029. PubMed: 19815012.
82. McFadyen MP, Kusek G, Bolivar VJ, Flaherty L (2003) Differences among eight inbred strains of mice in motor ability and motor learning on a rotorod. Genes Brain Behav 2: 214-219. doi:10.1034/j.1601-183X.2003.00028.x. PubMed: 12953787.
83. Joyce PI, Fratta P, Fisher EM, Acevedo-Arozena A (2011) SOD1 and TDP-43 animal models of amyotrophic lateral sclerosis: recent advances in understanding disease toward the development of clinical treatments. Mamm Genome 22: 420-448. doi:10.1007/s00335-011-9339-1. PubMed: 21706386.
84. Brooks SP, Jones L, Dunnett SB (2012) Comparative analysis of pathology and behavioural phenotypes in mouse models of Huntington's disease. Brain. Res Bull 88: 81-93. doi:10.1016/j.brainresbull.2011.10.002.
85. Lenzken SC, Romeo V, Zolezzi F, Cordero F, Lamorte G et al. (2011) Mutant SOD1 and mitochondrial damage alter expression and splicing of genes controlling neuritogenesis in models of neurodegeneration. Hum Mutat 32: 168-182. doi:10.1002/humu.21394. PubMed: 21120952.
86. Liang LP, Patel M (2004) Iron-sulfur enzyme mediated mitochondrial superoxide toxicity in experimental Parkinson's disease. J Neurochem 90: 1076-1084. doi:10.1111/j.1471-4159.2004.02567.x. PubMed: 15312163.
87. Pham AH, Meng S, Chu QN, Chan DC (2012) Loss of Mfn2 results in progressive, retrograde degeneration of dopaminergic neurons in the nigrostriatal circuit. Hum Mol Genet 21: 4817-4826. doi:10.1093/hmg/dds311. PubMed: 22859504.
88. Zhang J, Graham DG, Montine TJ, Ho YS (2000) Enhanced N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in mice deficient in CuZn-superoxide dismutase or glutathione peroxidase. J Neuropathol Exp Neurol 59: 53-61. PubMed: 10744035.
89. Cheng HC, Kim SR, Oo TF, Kareva T, Yarygina O et al. (2011) Akt suppresses retrograde degeneration of dopaminergic axons by inhibition of macroautophagy. J Neurosci 31: 2125-2135. doi:10.1523/JNEUROSCI.5519-10.2011. PubMed: 21307249.
90. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20: 415-455. doi:10.1016/0022-510X(73)90175-5. PubMed: 4272516.
91. Oliveras-Salva M, Van Rompuy AS, Heeman B, Van den Haute C, Baekelandt V (2011) Loss-of-function rodent models for parkin and PINK1. J Parkinsons Dis 1: 229-251
92. Raman AV, Chou VP, Atienza-Duyanen J, Di Monte DA, Bellinger FP et al. (2013) Evidence of oxidative stress in young and aged DJ-1-deficient mice. FEBS Lett 587: 1562-1570. doi:10.1016/j.febslet.2013.04.001. PubMed: 23587484.
93. Ben-Shachar D, Zuk R, Gazawi H, Ljubuncic P (2004) Dopamine toxicity involves mitochondrial complex I inhibition: implications to dopamine-related neuropsychiatric disorders. Biochem Pharmacol 67: 1965-1974. doi:10.1016/j.bcp.2004.02.015. PubMed: 15130772.
94. Hattoria N, Wanga M, Taka H, Fujimura T, Yoritaka A et al. (2009) Toxic effects of dopamine metabolism in Parkinson's disease. Parkinsonism Relat Disord 15 Suppl 1: S35-S38. doi:10.1016/S1353-8020(09)70010-0. PubMed: 19131041.
95. Kubo SI, Kitami T, Noda S, Shimura H, Uchiyama Y et al. (2001) Parkin is associated with cellular vesicles. J Neurochem 78: 42-54. doi:10.1046/j.1471- 4159.2001.00364.x. PubMed: 11432972.
96. Usami Y, Hatano T, Imai S, Kubo S, Sato S et al. (2011) DJ-1 associates with synaptic membranes. Neurobiol Dis 43: 651-662. doi:10.1016/j.nbd.2011.05. 014. PubMed: 21645620.
97. Jiang H, Jiang Q, Feng J (2004) Parkin increases dopamine uptake by enhancing the cell surface expression of dopamine transporter. J Biol Chem 279: 54380-54386. doi:10.1074/jbc.M409282200. PubMed: 15492001.
98. Jiang H, Ren Y, Yuen EY, Zhong P, Ghaedi M et al. (2012) Parkin controls dopamine utilization in human midbrain dopaminergic neurons derived from induced pluripotent stem cells. Nat Commun 3: 668. doi:10.1038/ncomms1669. PubMed: 22314364.
99. Keithley EM, Canto C, Zheng QY, Wang X, Fischel-Ghodsian N et al. (2005) Cu/Zn superoxide dismutase and age-related hearing loss. Hear Res 209: 76-85. doi:10.1016/j.heares.2005.06.009. PubMed: 16055286.